Cite
HARVARD Citation
Krop, I. et al. (2022). Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of clinical oncology. 40 (5), pp. 438-448. [Online].